Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepugratinib in Advanced Solid Tumors With FGFR3 Alterations
NCT05614739Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 1, open-label trial of vepugratinib in solid tumor, urothelial carcinoma (UC) and bladder cancer (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Overall Response Rate at 30 months, Area Under the Concentration versus Time Curve of Vepugratinib at 2 months and 2 more. Started Jan 2023; status: recruiting.
02
Drugs
vepugratinib
03
Conditions
solid tumorurothelial carcinoma (UC)bladder cancer
Beyond the preview
Go deeper on NCT05614739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614739.